CureVac Acquisition Enters Final Phase as BioNTech Integration Accelerates
Published on 01/02/2026 at 13:43 | Redaktion boerse-global.de
The new trading year has begun on a positive note for CureVac, with its shares posting significant gains. This upward movement reflects the market’s anticipation of the final stages of its acquisition by fellow German biotech firm BioNTech. Investor focus has now shifted to the technical completion of the deal and the timeline for CureVac’s eventual disappearance as an independent listed entity.
- Share Movement: Shares advanced approximately 4.5% to €3.78.
- Majority Stake: BioNTech already controls a commanding 81.74% of CureVac’s equity.
- Formal Completion: The transaction is expected to be formally finalized in January 2026.
- Management Shift: A key executive departure signals deepening integration efforts.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
